Objective-To investigate the role of acyl-CoA:cholesterol acyltransferase 1 (ACAT1) in hematopoiesis. Approach and Results-ACAT1 converts cellular cholesterol to cholesteryl esters for storage in multiple cell types and is a potential drug target for human diseases. In mouse models for atherosclerosis, global Acat1 knockout causes increased lesion size; bone marrow transplantation experiments suggest that the increased lesion size might be caused by ACAT1 deficiency in macrophages. However, bone marrow contains hematopoietic stem cells that give rise to cells in myeloid and lymphoid lineages; these cell types affect atherosclerosis at various stages. Here, we test the hypothesis that global Acat1 −/− may affect hematopoiesis, rather than affecting macrophage function only, and show that Acat1 −/− mice contain significantly higher numbers of myeloid cells and other cells than wild-type mice. Detailed analysis of bone marrow cells demonstrated that Acat1 −/− causes a higher proportion of the stem cell-enriched Lin − Sca-1 + c-Kit + population to proliferate, resulting in higher numbers of myeloid progenitor cells. In addition, we show that Acat1 −/− causes higher monocytosis in Apoe −/− mouse during atherosclerosis development.
A therosclerosis remains the leading cause of death and disability in the developed world. Statin drugs, potent inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase, are effective in reducing serum cholesterol levels. However, the residual risk for atherosclerosis after statin treatment remains significant, and alternative approaches have been developed to further combat atherosclerosis. One approach is to inhibit acyl-CoA:cholesterol acyltransferases (ACATs). 1 ACATs are membrane-bound enzymes that use long-chain fatty acylcoenzyme A and cholesterol as substrates to form cholesteryl esters. Mammals contain 2 isoenzymes, ACAT1 and ACAT2, which are encoded by 2 different genes. [1] [2] [3] The expression of ACAT1 is ubiquitous, 4 whereas the expression of ACAT2 is tissue restricted. 5 Both enzymes are drug targets for treating atherosclerosis. Macrophages play important roles in atherosclerosis. ACAT1 is the major isoenzyme in macrophages. 6 An ACAT1-specific small molecule inhibitor K604 inhibits macrophage foam cell formation in cell culture; when fed to the atherosclerotic Apoe −/− mouse at low concentration, K604 significantly diminishes the presence of lesion macrophages. 7 In addition, an isotype-nonspecific ACAT inhibitor F1394 at low concentration reduces progression of advanced atherosclerotic lesions in mice without plaque or systemic toxicity. 8 These studies suggest that partial inhibition of ACAT1 may be beneficial to treat atherosclerosis. On the contrary, mouse genetic experiments showed that in atherosclerotic Ldlr −/− or Apoe −/− mice, germline Acat1 gene ablation actually enlarged the lesion size of the plaque. 9, 10 These results raise caution against using ACAT1 inhibitors at high doses to treat atherosclerosis. Further investigation showed that when bone marrow (BM) isolated from Acat1 +/+ or Acat1 −/− animals was transplanted individually to lethally irradiated Ldlr −/− or Apoe −/− recipient mice, the atherosclerotic lesions were larger in mice receiving BM from the Acat1 −/− donor. Because BM contains myeloid progenitor cells that differentiate into monocytes/macrophages, these results suggest that the lack of Acat1 in macrophages may enlarge the lesions. 10 However, BM contains hematopoietic stem cells (HSCs) that give rise to cells in the myeloid lineages (eg, monocytes/macrophages, neutrophils, and dendritic cells) and cells in the lymphoid lineages (eg, T cells and B cells). Germline Acat1 loss may affect the function of HSC and the function of various cells derived from HSC. Recently, adenosine triphosphatebinding cassette (ABC) transporters A1 and G1 (ABCA1 and ABCG1), 2 key proteins involved in cellular cholesterol efflux, were shown to affect proliferation of HSCs and other progenitor cells in mouse BM. 11 In addition, lysosomal acid lipase, a key enzyme that produces cholesterol and free fatty acids from cholesteryl esters present in late endo/lysosomes, is shown to affect HSC proliferation. 12 In the current work, we test the hypothesis that germline Acat1 loss may affect HSC and other progenitor cell proliferation in BM.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Acat1 Knockout Mice Exhibit Leukocytosis
To test the hypothesis that global Acat1 loss may affect hematopoiesis, we first compared the numbers of monocytes, neutrophils, B cells, and T cells in peripheral blood of age-matched wild-type (WT) and Acat1 −/− mice. The results show that Acat1 −/− mice contain significantly higher numbers of monocytes (CD11b + ), neutrophils (Gr1 + ), and B cells (CD19 + ) in their blood compared with WT littermates ( Figure 1A ). The Acat1 −/− mice also contain slightly higher numbers of T cells than WT mice. In addition, their spleen size is bigger, and more cells are present in the lymph nodes compared with WT mice ( Figure I in the online-only Data Supplement). The body weights of WT and Acat1 −/− mice are the same for both males and females ( Figure I in the online-only Data Supplement). The increase in leukocytes in Acat1 −/− mouse could be caused by a cell-autonomous proliferation, or survival difference of cells within BM, and by change(s) in tissue microenvironment in these mice. To address this issue, we performed BM transplant experiments. BM cells from WT or Acat1 −/− mice were transplanted into lethally irradiated recipient WT mice to produce chimeric mice. Seven weeks after transplantation, Acat1 gene expression in leukocytes isolated from the chimeric mice was measured by real time-polymerase chain reaction and by Western blot. The results confirm that expression of both Acat1 mRNA and ACAT1 protein in mice transplanted with Acat1 −/− BM is <10% of that of mice transplanted with Acat1 +/+ BM ( Figure  IIA in the online-only Data Supplement, left and middle). We next monitored blood leukocyte numbers in chimeric mice at different time points, from 7 to 11 weeks after transplantation. The results show that leukocyte numbers in mice transplanted with Acat1 −/− BM are significantly higher than in mice transplanted with WT BM ( Figure 1B) . We also performed a parallel experiment using lethally irradiated Acat1 −/− mice as recipients of BM cells from either WT mice or Acat1 −/− mice. Again, as expected, Western blot and real-time-polymerase chain reaction analyses show that the expression of both Acat1 mRNA and ACAT1 protein in mice transplanted with Acat1 −/− BM is <10% of that found in mice transplanted with Acat1 +/+ BM ( Figure IIB in the online-only Data Supplement, left and middle). We then monitored leukocyte numbers in chimeric mice from 7 to 11 weeks after transplantation. The results show that leukocyte numbers in Acat1 −/− recipient mice ( Figure 1C ) were higher than those found in WT recipient mice ( Figure 1B ) when donor BM came from either the WT mice (comparing solid circles in Figure 1B and 1C) or the Acat1 −/− mice (comparing open circles in Figure 1B and 1C). Additional analysis shows that when WT BM donor cells were used, Acat1 −/− recipient mice had significantly higher leukocyte numbers than WT recipient mice (comparing solid circles in Figure 1B and 1C), suggesting the possibility that Acat1 −/− background/ microenvironment plays a significant role in causing leukocytosis. Other results show that the spleen weights of the chimeric mice with BM from Acat1 −/− mice are higher than those with BM from WT mice ( Figure IIA and IIB in the online-only Data Supplement, right). Together, these results suggest that Acat1 loss causes higher leukocyte numbers in the blood by affecting both cell-autonomous proliferation in BM and the microenvironment that supports hematopoiesis. Acat1 loss may also affect cell differentiation/self renewal or cell death. 13 The rest of the work presented here focuses on the cell-intrinsic effects of Acat1 −/− in hematopoietic cells in BM. 
Acat1 Loss Increases Hematopoietic Progenitor Cell Proliferation
To examine the effects of Acat1 loss on homeostasis of BM cells, we compared the number and the percentage of myeloid cell (Gr1 + CD11b + ) and B-cell (CD19 + ) lineages in the BM, isolated from age-matched (8-week-old) WT and Acat1 −/− mice.
The results show that Acat1 −/− BM contains higher numbers of cells in myeloid and B-cell lineages (Figure 2A ), whereas the percentages of these cells in WT and Acat1 −/− BM remain the same ( Figure 2B ). These results show that the Acat1 −/− BM has more cells of all lineages, suggesting that Acat1 −/− may affect HSCs or progenitor cell populations that differentiate into myeloid cells and other cell types. To test this possibility, we compared the number and percentage of the following progenitor cells: LSK (Lin − Sca-1 + c-Kit + ), common myeloid progenitor (CMP) (Lin − Sca-1 − c-Kit + CD34 + FcRII/III low ), granulocyte/macrophage progenitor (GMP) (Lin − Sca-1 − c-Kit + CD34 + FcRII/III + ), megakaryocyte/erythrocyte-restricted progenitor (Lin − Sca-1 − c-Kit + CD34 − FcRII/III − ), and common lymphoid progenitor (CLP; IL7α + Lin − Sca-1 mid c-Kit mid ) cells in BM isolated from WT and Acat1 −/− mice. The results show that the numbers of CMPs and GMPs in the Acat1 −/− BM were increased, whereas the numbers of LSKs, megakaryocyte/erythrocyte-restricted progenitors, and CLPs in WT and Acat1 −/− BM were similar ( Figure 3A ), suggesting that Acat1 −/− causes selective expansion of CMP and GMP progenitor populations and increases myeloid cell lineages in BM. The colony forming unit assay in vitro has been used to estimate the frequency of primitive hematopoietic progenitor cells committed to the myeloid lineages. We enumerated colony forming units and showed that Acat1 −/− mouse BM produced significantly more colonies than the WT mouse BM; on the basis of morphology analysis, Acat1 −/− caused increases in several different progenitor cell types, including granulocyte, macrophage, and granulocyte/macrophage ( Figure III in the online-only Data Supplement). Next, we performed bromodeoxyuridine (BrdU) incorporation assays to monitor cell proliferation in WT and Acat1 −/− mouse BM in vivo. The results show that when compared with WT BM, the LSK cells, but not other cell populations in Acat1 −/− BM, exhibited a higher percentage of BrdU incorporation ( Figure 3B ), supporting the interpretation that increased numbers of CMPs, GMPs, and myeloid cells observed in Acat1 −/− BM ( Figure 3A ) are mainly because of higher proliferation in Acat1 −/− LSK cells. In parallel experiments, we also quantified apoptotic cells in vivo in WT and Acat1 −/− BM using the Annexin V staining assay. The results ( Figure 3C) show that no significant difference in apoptotic cells can be detected between WT and Acat1 −/− BM.
In an effort to confirm the finding that Acat1 −/− enhances specific LSK cell proliferation at the in vitro level, we isolated various progenitor cells by cell sorting, including LSKs, CMPs, and GMPs, from BM of WT and Acat1 −/− mice. The cytokine interleukin 3 (IL3) supports proliferation in several myeloid progenitor populations. 14 BrdU incorporation. These results are in accord with the in vivo data and demonstrate that Acat1 −/− LSK cells proliferate more frequently in vivo and in vitro. Further analysis of LSK cell subpopulations, including long-term HSCs (LSK/ CD34 − CD135 − ), short-term HSCs (LSK/CD34 + CD135 − ), and multi-potent progenitors (LSK/CD34 + CD135 + ), showed that Acat1 −/− causes a small but statistically significant selective increase in multi-potent progenitor subpopulation within LSK cells ( Figure V in the online-only Data Supplement).
Acat1 −/− Increases BM Cell Proliferation by Activating the ERK Pathway
Yvan-Charvet et al 11 showed that on stimulation by IL3 for 72 hours in vitro, BM isolated from ABCA1/ABCG1 double knockout (DKO) mouse exhibited increased cell proliferation, mainly through activated phospho-extracellular signal-regulated kinase (p-ERK) pathway, implying that aberrant ERK signaling may mediate the effects of Acat1 −/− on LSK cell proliferation. To test this possibility, we first cultured WT and Acat1 −/− BM cells in 10% fetal bovine serum supplemented with various cytokines (stem cell factor or IL3 or granulocyte-macrophage-colony stimulating factor as indicated) and then monitored their proliferation rates using a 3H-thymidine pulse. The results ( Figure 4A ) showed that both the IL3-treated and the granulocyte-macrophage-colony stimulating factor-treated Acat1 −/− BM cells, but not the stem cell factor-treated Acat1 −/− BM cells, had significantly higher cell proliferation than their WT counterparts ( Figure 4A) , indicating that the IL3-dependent BM cell proliferation in vitro is enhanced by Acat1 loss. We next compared the degree of p-ERK activation in IL3-treated WT and Acat1 −/− BM cells. The results of a Western blot analysis showed that in response to IL3 treatment, Acat1 −/− cells exhibited enhanced p-ERK compared with WT cells ( Figure 4B ). To validate the result shown in Figure 3A , we took a different approach using flow cytometry to monitor cell populations with double positive signals in p-ERK and CD11b after IL3 treatment. The results showed that the Acat1 −/− BM cell culture exhibited a higher percentage of p-ERK + CD11b + cells than the WT counterpart (30% versus 13%; Figure 4C ). We next treated WT and Acat1 −/− BM cell cultures with 2 different ERK signaling pathway inhibitors, MAPK/ERK kinase inhibitor (U0126) and Src tyrosine kinase inhibitor (PP2). 15, 16 The results show that both inhibitors partially alleviated the higher 3H-thymidine incorporation phenotype observed in the Acat1 −/− BM cells ( Figure 4A ), supporting the conclusion that Acat1 −/− enhances the ERK signaling pathway in BM myeloid cells. The IL3Rβ subunit is shared by the IL3 and granulocyte-macrophage-colony stimulating factor receptors and plays a critical role in the receptor-mediated ERK signaling pathway. 11, 16 We assessed cell surface IL3Rβ expression and found that in Acat1 −/− BM, the IL3Rβ signal is increased in LSK cells, and in the bulk BM cells in vivo ( Figure 5A ). In addition, we found that cell surface IL3Rβ expression is increased in Acat1 −/− BM cell culture under IL3 treatment in vitro, when compared with its WT counterpart (42% versus 60%; Figure 5B ). Taken together, these results support the conclusion that Acat1 −/− LSK cells exhibit enhanced IL3-dependent proliferation because of increased IL3Rβ expression and thus enhanced ERK signaling. Interestingly, increased cell surface IL3Rβ expression was also observed in BM lacking both ABCA1 and ABCG1. ACAT1 converts cholesterol to cholesteryl esters and prevents the accumulation of free cholesterol in various cell membranes. 1 IL3Rβ is mainly expressed at the plasma membrane. 16 Signaling of IL3 through IL3Rβ is affected by cellular membrane lipid composition. The effect of Acat1 −/− on IL3 signaling may be attributed to a change in the cholesterol content in BM cells. To test this possibility, we used a small molecule squalene synthase inhibitor CP-340868, which blocks the biosynthesis of squalene from farnesyl pyrophosphate. At micromolar concentrations, this inhibitor effectively shuts down cholesterol biosynthesis without inhibition of nonsterol polyisoprenoid biosynthesis and protein prenylation. 17 We incubated WT and Acat1 −/− BM cells with IL3 in the presence or absence of CP-340868 and found that treating cells with CP-340868 reversed the enhanced cell proliferation observed in Acat1 −/− BM cells ( Figure VI in the online-only Data Supplement; lanes 2 and 3). The result of a parallel experiment showed that adding ApoA1, a cellular cholesterol efflux mediator (at 50 or 100 µg/ mL), to the cell culture did not diminish the enhanced proliferation observed in Acat1 −/− BM cells ( Figure VI in the onlineonly Data Supplement; lanes 4 and 5). These results suggest that de novo cholesterol synthesis in BM cells is required to mediate the effect of Acat1 −/− on cell proliferation.
Acat1 −/− Animals Exhibit an Increase in B-Cell Progenitors
We showed earlier ( Figure 1A ) that in Acat1 −/− mouse blood, in addition to the myeloid cell number, the B-cell number (CD19 + ) is also increased. The CLP cell is the major progenitor for B lineage-restricted cells. However, no difference in either absolute number or percentage of CLPs can be found between WT and Acat1 −/− BM ( Figure 3A) . These results imply that Acat1 loss may affect B-cell progenitor populations downstream of CLPs. To test this possibility, we monitored specific B-cell progenitor populations and found that when compared with WT, the pre-B-cell population, but not the pro-B-cell population, was increased in Acat1 −/− BM ( Figure 6A, left) . The percentage of B-cell progenitors in WT and Acat1 −/− BM was the same (Figure 6A, right) . We next found that the BrdU incorporation in vivo was slightly but statistically higher in Acat1 −/− pro-B cells than their WT counterparts ( Figure 6B , left; P value <0.01). The result of a parallel experiment showed that apoptotic cells in vivo (as quantified by Annexin V staining) were reduced in the Acat1 −/− pro-B-cell populations when compared with the WT counterpart ( Figure 6B,  right) . In B-cell progenitors, the IL7 receptor α subunit plays a key role both in survival and in proliferation. 13 We compared the expression of cell surface IL7Rα in BM B cells and found that its expression is elevated in Acat1 −/− pro-B cells compared with WT pro-B cells ( Figure 6C ). This result suggests that Acat1 loss facilitates proliferation of pro-B cells in part through elevated cell surface IL7Rα expression, similar to our findings with the IL3Rβ in the myeloid lineage.
Acat1 −/− Causes Higher Monocytosis in Apoe −/− Mouse During Atherosclerosis Development
Monocytes and macrophages play key roles in atherosclerosis development. In mouse models for atherosclerosis, global Acat1 gene ablation enlarged the lesion size of the plaque. 9, 10 On the basis of results described above, we suspect that Acat1 −/− may affect blood monocyte counts during atherosclerosis development. To test this possibility, we crossed Apoe −/− mice with Acat1 −/− mice to generate Apoe −/− /Acat1 −/− (DKO) mice. We then fed age-matched male Apoe −/− and DKO mice with modified Paigen's diet for 0 to 6 weeks and monitored blood myeloid (CD11b + Gr1 + ) cell numbers at various time points. The results showed that from 0 to 2 weeks blood myeloid cell numbers in the DKO mice tended to be higher than those in the Apoe −/− mice, but the difference did not reach statistical significance. From 4 to 6 weeks, in the Apoe −/− mice blood myeloid cell numbers began to increase; this finding is consistent with an earlier published result demonstrating that Apoe −/− promotes monocytosis in mice 18 ; in the DKO mice, the increase in monocytes was much higher ( Figure VII Acat1 −/− causes higher monocytosis in the Apoe −/− mouse during atherosclerosis development. Accelerated monocytosis may partially account for the previous observation that global Acat1 −/− exaggerates lesion formation in atherosclerotic mice.
Discussion
Here, we showed that in normal mice on normal diet, Acat1 −/− in BM increases peripheral blood leukocytes. The monocytes, neutrophils, and B cells in Acat1 −/− mice are significantly higher in absolute number than those in the normal, Acat1 +/+ mice. The leukocytosis phenotype is attributed to both cellautonomous mechanism and environmental influences. We performed additional experiments to explore the cell-autonomous mechanism(s). The results show that Acat1 loss causes leukocytosis mainly by increasing LSK and pro-B-cell proliferation, through upregulation of their cell surface IL3Rβ and IL7Rα expression. Recently, 2 other studies involving cholesterol homeostasis have reported similar findings. Yvan-Charvet et al 11 showed that ABCA1 and ABCG1 DKO in mice increases LSK cell proliferation and causes leukocytosis; Qu et al 12 showed that lysosomal acid lipase KO in mice increases LSK cell proliferation and results in increased numbers of macrophages and neutrophils in peripheral blood. These studies together suggest that cellular cholesterol homeostasis plays important roles in hematopoiesis. Why should cholesterol homeostasis affect hematopoiesis? Lipid rafts are cholesterolrich and sphingolipid-rich microdomains in cell membranes and participate in membrane-dependent signal transduction. 19 Cellular cholesterol homeostasis can cause structural and functional changes in lipid rafts. Our study and the work of others 11,12 support the concept that lipid rafts play important roles in cell signaling in hematopoiesis.
ACAT1 inhibitors are drug candidates for treating atherosclerosis and Alzheimer disease. 20 Our study suggests that complete inhibition of ACAT1 in systemic tissues may cause leukocytosis. Because chronic leukocytosis may be a risk factor for atherosclerosis, 21 measuring leukocyte counts may serve as a biomarker for safety study when testing ACAT1 inhibitor as a drug. However, chemotherapy and high-dose radiation therapy result in leukopenia; poorly controlled or untreated leukopenia can be life-threatening. Our current study implies that inhibiting ACAT1 systemically can be beneficial for acute treatment of leukopenia and the resulting immunosuppressionassociated diseases.
Cells in both myeloid and lymphoid lineages affect atherosclerosis at various stages. Interpretation of results obtained with BM transplant needs to consider possible involvement of all other cell types in BM, in addition to monocytes/macrophages. Higher monocytosis caused by global Acat1 −/− could be one of the factors leading to the increased lesion size seen in atherosclerotic mice. To investigate the pathophysiological roles of ACAT1 in macrophages and in other cell types/ tissues, we are currently taking a mouse genetic approach to inactivate the ACAT1 gene in a cell-type-specific manner.
